Nika Pharmaceuticals Inc.
NIKA · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $8 | $18 | $13 | $12 |
| SG&A Expenses | $8 | $18 | $13 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$46 |
| Operating Expenses | $8 | $18 | $13 | -$34 |
| Operating Income | -$8 | -$18 | -$13 | $33 |
| % Margin | – | – | – | -21,386.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$8 | -$18 | -$13 | $33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$18 | -$13 | -$12 |
| % Margin | – | – | – | 7,982.7% |
| EPS | 0 | 0 | 0 | 0 |
| % Growth | – | – | -100% | – |
| EPS Diluted | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out | 1,039,836 | 1,026,406 | 1,026,371 | 1,018,520 |
| Weighted Avg Shares Out Dil | 1,039,836 | 1,026,406 | 1,026,371 | 1,018,520 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $12 |
| EBITDA | -$8 | -$18 | -$13 | $11 |
| % Margin | – | – | – | -6,827.6% |